title: [Adjuvant treatments of non-small cell lung cancer].
abstract: If surgery remains the cornerstone for the curative treatment of non-small cell lung cancer, failures are common especially for stage III disease and adjuvant treatment (chemotherapy or radiotherapy) may be justified. After the two meta-analyses, new trials have showed a moderate but significant benefit from cisplatin based chemotherapy. The role of radiotherapy is still controversial but from some clinical observations, a new trial using the modern radiation technology should address the question.
authors.affiliation: Département de radio-oncologie, institut Jules-Bordet, 121, boulevard de Waterloo, 1000 Bruxelles, Belgique.
authors.forename: L
authors.initials: L
authors.lastname: Moretti
authors.forename: M
authors.initials: M
authors.lastname: Roelandts
authors.forename: T
authors.initials: T
authors.lastname: Berghmans
authors.forename: P
authors.initials: P
authors.lastname: Van Houtte
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000601:surgery*; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant
chemical_list: D002945:Cisplatin